One small startup is stepping up in the fight against COVID-19.
You may have never heard of 20/20 GeneSystems. But members of our First Stage Investor research service have. We recommended they invest in 20/20 back in 2017.
And now 20/20 is doing something we could not have predicted in 2017. This dynamic startup is gearing up to provide COVID-19 tests.
The company’s main business (and why we recommended you invest in it in the first place) is layering artificial intelligence over the top of blood tests to help detect cancer in its earliest stages.
An increasing number of people have used its tests here in the U.S. I’ve taken the cancer test myself. It’s the only test I know that can tell me if I’m in danger of developing cancer. (I tested positive.)
Like the rest of the country, 20/20 saw the novel coronavirus explode in the U.S. and wondered if it could help. Now it’s moving quickly to bring a rapid COVID-19 blood test to the market in the U.S.
The company believes it can help fix the nation’s shortage of COVID-19 tests. And it wants to capture at least 5% of the COVID-19 testing market.
This is great news for our country. We desperately need the test that 20/20 is hoping to bring to market as soon as next week. It’s also good news for investors. The company is in the middle of raising funds. And right now, you can buy its shares at a price that was determined before the coronavirus appeared. In other words, you’d be buying into an explosive growth opportunity at a heavily discounted price.
This is such an outstanding opportunity that we decided it shouldn’t be limited just to paying members of our startup research service. The best way to share with you what the company is doing is to have you hear more about it from the founder himself, Jonathan Cohen.
Early Investing, along with KingsCrowd (a San Francisco-based startup rating company), will be hosting an exclusive live webinar with Jonathan and his lieutenants this Thursday, April 2, from 3 p.m. to 4 p.m. ET (noon to 1 p.m. on the West Coast). Just click here to register.
Jonathan will be answering these questions (among others)…
- What exactly is the rapid blood test 20/20’s making available in the U.S.?
- What does it do that current swab tests don’t do?
- How big is the market for these tests?
- Who will be 20/20’s biggest customers?
- How can you invest in 20/20’s current raise?
The webinar will include a Q&A session, where you can ask Jonathan and his lieutenants anything you want.
If you want to learn more about this new test and unique investment opportunity, just click here to register. If you’ve already signed up, this serves as a reminder to join us tomorrow at 3 p.m. ET.
20/20 GeneSystems illustrates how very small companies can tackle very big problems. And, many times, they do it more effectively than larger companies with more resources and money to draw upon.
This company also represents the classic value proposition of startups. Its shares go for a pittance. And for good reason. Attacking huge problems often ends in failure. But success is richly rewarded, for founders and early investors alike.
20/20 GeneSystems is rushing to the aid of a country in desperate need of its tests. Whether or not you want to invest, its story alone is worth hearing. But it’s also a chance to weigh a potentially incredible investment opportunity.
Hope to see you at our webinar beginning tomorrow at 3 p.m. Click here if you wish to join us.